PARP Inhibitors in the Management of Ovarian Cancer

Publication Date: September 23, 2022

Key Points

Key Points

  • These recommendations pertain only to patients with epithelial ovarian, tubal, or primary peritoneal cancer who have not previously received a poly(ADP-ribose) polymerase inhibitors (PARPi).
  • The recommendations are based on clinical trial results and FDA approvals and do not necessarily capture regulatory approvals in other jurisdictions.

Treatment

Treatm...

Repeating P...

...on 1.0Repeating PARPi therapy in the treatmen...


...agnosed Ovarian Cancer...

...2.0PARPi are NOT recommended for use in initia...

...€“ Recommendation 2.1Patients with new...

...mendation 2.2The addition of olaparib...

...commendation 2.3Inclusion of the PARPi, v...


...nt Ovarian Cancer - Second-line or Gr...

...e – Recommendation 3.0...

...erapy maintenance (second-line or more) may be of...

Maintenance treatment with nirapari...

...apid Update – Recommendation 3.1/3...

...te – Recommendation 3.3PARPi monoth...


...RPi in Combination...

...commendation 4.0PARPi are NOT recommended for use...


...ent of Adverse Event...

...endation 5.0 Anemia...

...equiring a blood transfusion for sympto...

...ients with progressive anemia may be offered gr...

Recommendation 5.1 Neut...

...is NOT indicated for use in patie...

...openia (grade 4 lasting at least 5–7 days or...

...ecommendation 5.2 Platelet...

...penia is most common with niraparib. Nirap...

...ARPi for persistent thrombocytopenia or signif...

Recommendation 5.3 Persistent cytopenia:E...

...ommendation 5.4 Naus...

...ts will have tachyphylaxis of nausea symptoms ov...

...tent nausea requiring daily anti-emetic i...


...nhibitors in the Management of Ovarian Can...


...igure 1. PARPi Use Opportunities in PARPi-N...